The stock of Aurinia Pharmaceuticals Inc (TSE:AUP) is a huge mover today! About 49,485 shares traded hands. Aurinia Pharmaceuticals Inc (TSE:AUP) has declined 1.06% since March 30, 2016 and is downtrending. It has underperformed by 2.28% the S&P500.
The move comes after 5 months positive chart setup for the $143.21M company. It was reported on Nov, 3 by Barchart.com. We have $5.70 PT which if reached, will make TSE:AUP worth $67.31M more.
Another recent and important Aurinia Pharmaceuticals Inc (TSE:AUP) news was published by 247Wallst.com which published an article titled: “Aurinia Pharmaceuticals Jumps on Phase 3 Trial Plans” on November 03, 2016.
Aurinia Pharmaceuticals Inc. is a Canada clinical-stage biopharmaceutical firm operating in the field of nephrology and autoimmunity. The company has a market cap of $143.21 million. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis . It currently has negative earnings. It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.